PMADS

Id:	acc1797
Group:	2sens
Protein:	GSTP1
Gene Symbol:	GSTP1
Protein Id:	P09211
Protein Name:	GSTP1_HUMAN
PTM:	phosphorylation
Site:	Tyr7
Site Sequence:	---MPPYTVVYFPVRGRCAAL
Disease Category:	Cancer
Disease:	Glioma
Disease Subtype:
Disease Cellline:	MGR1
Disease Info:
Drug:	Cisplatin
Drug Info:	"Cisplatin is a platinum-based chemotherapeutic agent widely used in the treatment of various malignancies, including ovarian, bladder, testicular, and non-small cell lung cancers, by forming DNA cross-links to interfere with replication and repair, thereby inhibiting cancer cell growth and proliferation."
Effect:	decrease
Effect Info:	"In human glioma and breast cancer cells, epidermal growth factor stimulation rapidly increases tyrosine phosphorylation of GSTP1 and reduces cisplatin sensitivity."
Note:
Score:	5.0
Pubmed(PMID):	19254954
Sentence Index:	19254954_5-6
Sentence:	"The phosphorylation increased GSTP1 enzymatic activity significantly, and computer-based modeling showed a corresponding increase in electronegativity of the GSTP1 active site. In human glioma and breast cancer cells, epidermal growth factor stimulation rapidly increased GSTP1 tyrosine phosphorylation and decreased cisplatin sensitivity."

Sequence & Structure:

MPPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCLYGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVEDLRCKYISLIYTNYEAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGDQISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYVGRLSARPKLKAFLASPEYVNLPINGNGKQ

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target	Drug name	MOA	Phase	Status	Disease	Source
GSTP1	EZATIOSTAT HYDROCHLORIDE	Glutathione S-transferase Pi inhibitor	2	Completed	myelodysplastic syndrome	ClinicalTrials
GSTP1	EZATIOSTAT	Glutathione S-transferase Pi inhibitor	2	Terminated	myelodysplastic syndrome	ClinicalTrials ClinicalTrials
GSTP1	EZATIOSTAT HYDROCHLORIDE	Glutathione S-transferase Pi inhibitor	2	Terminated	myelodysplastic syndrome	ClinicalTrials ClinicalTrials
GSTP1	EZATIOSTAT	Glutathione S-transferase Pi inhibitor	2	Completed	myelodysplastic syndrome	ClinicalTrials
GSTP1	EZATIOSTAT HYDROCHLORIDE	Glutathione S-transferase Pi inhibitor	2	Terminated	non-small cell lung carcinoma	ClinicalTrials
GSTP1	EZATIOSTAT	Glutathione S-transferase Pi inhibitor	2	Terminated	non-small cell lung carcinoma	ClinicalTrials
GSTP1	EZATIOSTAT HYDROCHLORIDE	Glutathione S-transferase Pi inhibitor	2	Terminated	severe congenital neutropenia	ClinicalTrials
GSTP1	EZATIOSTAT	Glutathione S-transferase Pi inhibitor	2	Terminated	severe congenital neutropenia	ClinicalTrials
GSTP1	EZATIOSTAT HYDROCHLORIDE	Glutathione S-transferase Pi inhibitor	1	Completed	myelodysplastic syndrome	ClinicalTrials ClinicalTrials
GSTP1	EZATIOSTAT	Glutathione S-transferase Pi inhibitor	1	Completed	myelodysplastic syndrome	ClinicalTrials ClinicalTrials ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets

Small molecule

Antibody

PROTAC

Other modalities

Approved Drug

Advanced Clinical

Phase 1 Clinical

Structure with Ligand

High-Quality Ligand

High-Quality Pocket

Med-Quality Pocket

Druggable Family

Approved Drug

Advanced Clinical

Phase 1 Clinical

UniProt loc high conf

GO CC high conf

UniProt loc med conf

UniProt SigP or TMHMM

GO CC med conf

Human Protein Atlas loc

Approved Drug

Advanced Clinical

Phase 1 Clinical

Literature

UniProt Ubiquitination

Database Ubiquitination

Half-life Data

Small Molecule Binder

Approved Drug

Advanced Clinical

Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

GSTP1-Ser135
Cancer	Intensity
BRCA
COAD	0.707
HGSC	-0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

GSTP1-Ser28
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	-0.707
GBM
HNSC
LUAD	0.707
LUSC
non_ccRCC
PDAC
UCEC

GSTP1-Ser43
Cancer	Intensity
BRCA
COAD
HGSC	-1.404
ccRCC
GBM	0.409
HNSC	-0.071
LUAD	-0.86
LUSC
non_ccRCC	-0.19
PDAC	1.707
UCEC	0.408

GSTP1-Ser47
Cancer	Intensity
BRCA
COAD
HGSC	0.349
ccRCC	-0.569
GBM
HNSC	0.828
LUAD	0.721
LUSC	1.032
non_ccRCC
PDAC	-0.681
UCEC	-1.68

GSTP1-Thr132
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC	-0.966
LUAD	-0.064
LUSC
non_ccRCC	1.03
PDAC
UCEC

GSTP1-Thr35
Cancer	Intensity
BRCA	-0.943
COAD
HGSC
ccRCC	-0.56
GBM
HNSC	1.113
LUAD	1.056
LUSC	-0.666
non_ccRCC
PDAC
UCEC

GSTP1-Thr38
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC	-0.05
GBM
HNSC	-0.974
LUAD	1.024
LUSC
non_ccRCC
PDAC
UCEC

GSTP1-Thr62
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC	-0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC	0.707

GSTP1-Tyr199
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC	0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC	-0.707

PTM-Disease Association:

source: PTMD

Residue	Position	State	Disease	Class	PMID
-	-	D	Colorectal cancer	Ubiquitination	31024008
S	42	U	Glioblastoma	Phosphorylation	15604283
S	184	U	Glioblastoma	Phosphorylation	15604283

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links:

CTD
DMRdb